← All trials
NCT05215470
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 18, 2022
- Primary completion
- Nov 30, 2024
- Completion date
- Nov 30, 2026
- First posted
- Jan 31, 2022
- Last posted
- Feb 1, 2022
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Ribeirao PretoLead sponsor
- Fundação de Amparo à Pesquisa do Estado de São PauloCollaborator
- University of Ribeirao PretoReponsible party - principal investigator
- University of Sao PauloOverall official - principal investigator
- University of Ribeirao PretoSponsor investigator
- University of Sao PauloOfficial
- Bristol-Myers SquibbCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.